F-1: Phaos Technology Faces Going Concern Doubts Amidst Losses

Phaos Technology Holdings (Cayman) Limited reports continued operating losses and substantial doubt about its ability to continue as a going concern, despite a recent IPO and revenue growth in microscopy products.

Summary

• Phaos Technology Holdings (Cayman) Limited, an investment holding company incorporated on March 7, 2024, specializes in advanced microscopy solutions, technologies, and products, utilizing patented microsphere-assisted technology.
• The company's solutions offer super-resolution imaging down to 137nm, significantly exceeding traditional optical microscope limits of 200-250nm, and include proprietary AI-powered software for pattern recognition in research, QA/QC, and diagnostics.
• Microscopy products contributed 80.9% and 92.5% of revenue for the six-month periods ended October 31, 2024 and 2025, respectively.
• Revenue increased by 38.8% to S$87,617 (US$67,334) for the six-month period ended October 31, 2025, from S$63,129 for the same period in 2024.
• Net loss decreased by 25.4% to S$1,505,248 (US$1,156,784) for the six-month period ended October 31, 2025, compared to S$2,019,092 for the same period in 2024.
• Accumulated deficit increased by 51.1% to S$13,672,378 (US$10,507,222) as of October 31, 2025, from S$9,049,158 as of October 31, 2024.
• For the year ended April 30, 2025, revenue was S$167,707 (US$128,464), a 91.1% decrease from S$1,882,803 in 2024, primarily due to reduced sales orders from largest customers.
• Net loss for the year ended April 30, 2025, was S$5,137,064 (US$3,934,994), an increase of 117.7% from S$2,359,844 in 2024.
• The company completed an IPO on November 12, 2025, selling 2,700,000 Class A ordinary shares at $4.00 per share, and underwriters exercised an over-allotment option for an additional 405,000 shares on November 24, 2025, generating net proceeds of approximately US$9,400,220.
• A loan of S$1,623,608 (US$1,243,683) to PT Neura Integrasi Solusi for biomedical scanning software development was partially impaired by S$1,223,608 (US$937,284) as of April 30, 2025, with a reversal of impairment of S$102,283 (US$78,605) by October 31, 2025, after repayments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' warning, significant accumulated losses, and a substantial revenue decline in the last fiscal year, despite a recent IPO and some positive operational improvements in the most recent six-month period.

Positives

• Proprietary microsphere-assisted technology allows for super-resolution imaging down to 137nm, a significant competitive advantage over traditional optical microscopes.
• Integrated in-house AI software enhances product performance, offering precise control, automation, and data analysis for research, QA/QC, and diagnostics.
• Offers turn-key solutions tailored to customer needs, avoiding unnecessary expenses and providing comprehensive, customized implementations.
• Provides reliable after-sales support with dedicated experts and a software development team, fostering customer satisfaction and loyalty.
• Established a sales network in Asia, with solutions sold to customers in Singapore, Indonesia, the Philippines, Malaysia, Thailand, India, China, and South Korea.
• Revenue for the six-month period ended October 31, 2025, increased by 38.8% to S$87,617 compared to the same period in 2024, driven by customer base diversification and cost management.
• Net loss decreased by 25.4% for the six-month period ended October 31, 2025, compared to the same period in 2024, indicating improved cost management.
• Gross margin improved to 41.8% for the six-month period ended October 31, 2025, from 12.7% in the prior year, due to improved product mix and efficient resource utilization.
• Successful completion of an IPO in November 2025, raising approximately US$9,400,220 in net proceeds, providing additional liquidity.
• Strategic loan to PT Neura Integrasi Solusi aims to build alliances in Indonesia's biomedical sector, with PT Neura receiving international recognition and a strategic investment valuing them at US$5 million.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses and a significant accumulated deficit.
• Cash balance as of October 31, 2025, was only S$54,989 (US$42,259), with negative cash flow from operations of S$1,291,946 (US$992,859) for the six-month period then ended.
• Revenue for the year ended April 30, 2025, decreased by 91.1% to S$167,707 from S$1,882,803 in 2024, primarily due to a reduction in sales orders from largest customers.
• Net loss for the year ended April 30, 2025, increased by 117.7% to S$5,137,064 (US$3,934,994) from S$2,359,844 in 2024.
• High customer concentration, with the top five customers accounting for 85% of total revenue for the six-month period ended October 31, 2025, and the largest customer accounting for 26.2%.
• Geographic concentration, with 83.3% of revenue for the six-month period ended October 31, 2025, derived from Singapore, exposing the company to regional economic risks.
• Workforce reduced from 25 employees as of April 30, 2025, to 10 full-time employees as of October 31, 2025, which may impact growth objectives and service capabilities.
• Significant impairment of S$1,223,608 (US$937,284) on the loan to PT Neura Integrasi Solusi as of April 30, 2025, indicating high risk associated with this investment.
• Dependence on interest-free, unsecured, and due-on-demand loans from major shareholder Tonghuai SG Enterprise Pte. Ltd. (S$3,755,423 or US$2,886,043 as of October 31, 2025) poses a material risk to liquidity if called for repayment.
• Identified material weaknesses in internal controls over financial reporting, including a lack of sufficient skilled staff with U.S. GAAP and SEC reporting knowledge, and a lack of formal accounting policies and procedures manual.

Risks

• Incurred operating losses since inception and substantial doubt about ability to continue as a going concern, requiring additional capital.
• Susceptible to fluctuations in prices and quantity of materials and components used in manufacturing microscopy equipment.
• Reputation and profitability may be adversely affected by major failures or malfunctions in microscopy equipment.
• Significant failure or deterioration in quality control systems could materially adversely affect business and operating results.
• Risk of being in breach of lease agreements, potentially leading to significant remediation costs.
• Increased competition in the microscopy equipment sales and rental business in Singapore and the region may affect market share and growth.
• Exposed to credit risks of customers, with average accounts receivable turnover days of 179 days as of October 31, 2025.
• Business is subject to supply chain interruptions, including disruptions in delivery capabilities, failure of third-party service providers, and rising transportation expenses.
• Exposed to risks arising from fluctuations of foreign currency exchange rates.
• May not be able to obtain necessary approvals or certifications for the use of microscopy equipment in various jurisdictions.
• Harm from negative publicity, especially given reliance on word-of-mouth referrals.
• Inability to maintain and protect intellectual property, or third-party assertions of infringement, could harm the business.
• Subject to risks related to product recalls, which could significantly impact operations and financial condition.
• Inability of PT Neura Integrasi Solusi to meet financial obligations on the loan provided could have a material adverse effect on results.
• An active trading market for Class A Ordinary Shares may not be established or continue, and the trading price may fluctuate significantly.
• May not maintain the listing of Class A Ordinary Shares on NYSE American, limiting investor transactions and subjecting the company to additional trading restrictions.
• Extreme volatility in stock price, potentially unrelated to underlying performance, making it difficult for investors to assess value.
• Failure to implement and maintain an effective system of internal controls and/or financial reporting may lead to reporting failures or fraud.
• Investors purchasing Class A Ordinary Shares in this offering may experience immediate and substantial dilution.
• Public offering price may not be indicative of prevailing market prices, and market prices may be volatile.
• Major shareholder has substantial influence over the company, and their interests may not align with other shareholders.
• As a Cayman Islands company, permitted to follow certain home country corporate governance practices in lieu of NYSE standards, potentially affording less protection to shareholders.
• Judgments obtained against the company or its auditor by shareholders may not be enforceable due to incorporation in Cayman Islands and operations in Singapore.
• As an emerging growth company and foreign private issuer, eligible for reduced reporting requirements, which may provide less information to investors.
• May lose foreign private issuer status in the future, resulting in significant additional costs and expenses.
• Compensation of directors and officers may not be publicly available under Cayman Islands law.
• Incur significantly increased costs and devote substantial management time as a result of NYSE listing.
• Exposure to acts of war, terrorist attacks, epidemics, political unrest, adverse weather conditions, and other uncontrollable events.
• Inadequate insurance policies to cover assets, operations, and business interruptions.
• Inability to successfully implement business strategies and future plans, including product diversification and joint ventures.
• Inflation risk, driving up raw material, component, transportation, energy, and labor costs.

Future Outlook

The company plans to expand its business and operations through joint ventures and strategic alliances in Southeast Asia, China, Taiwan, and Korea, leveraging digital marketing and physical presence at exhibitions in the Middle East, the United States, and Europe. It aims to strengthen its distribution network and widen its product range by continuously improving existing products, developing new series for biomedical applications (e.g., digital pathology for cancer cell analysis), and integrating new technologies like Optical Coherence Tomography, IoT, and cloud computing solutions. The company also intends to build databases to train its AI software for pathology and metrology use cases and provide calibration and certification services by Q2 2025 to generate recurring income.

Management Comments

• "We expect that the diversification of our customer base will allow us to increase and stabilize our product sales through a larger customer base and lower concentration of top customers which we are working actively to broaden."
• "Service revenue increased as a result of maintenance-based contracts for our customers. As we grow our product and software range, we expect that service revenue will continue to contribute a greater percentage of our revenue going forward."
• "We believe in our strong corporate culture which emphasizes the creation of shareholder value."
• "Management has commenced a strategy to raise debt and equity. However, there can be no certainty that these additional financings will be available on acceptable terms or at all. If management is unable to execute this plan, there will likely be a material adverse effect on the Company's business."
• "There is no immediate liquidation concern for the Company; however, there is substantial doubt on the Company being a going concern but the management has positive mitigation plan to handle going concern issue."

Industry Context

StockSavvy.ai notes that Phaos Technology operates in the highly competitive microscopy equipment industry, facing established players with greater scale and financial resources. Its patented microsphere-assisted technology, offering super-resolution imaging below the 200nm optical limit, positions it as a niche innovator. The strategic focus on integrating AI software and expanding into biomedical applications aligns with broader industry trends towards advanced imaging, automation, and digital health solutions. However, the company's significant customer and geographic concentration, coupled with its early revenue stage and ongoing losses, highlight the challenges of scaling in a market dominated by larger, diversified competitors.

Comparison to Industry Standards

• Phaos Technology's super-resolution imagers capable of achieving imaging down to 137nm surpass traditional optical microscopes which typically see up to 250nm, offering a competitive edge in resolution.
• Competitors mentioned include Keyence Corp. (TYO:6861) with its IM Series and VHX Series, Nikon Corp. (TYO:7731) with its LV Series and ECLIPSE Series, Olympus Corp. (TYO:7733) with its MX Series, DSX Series and CX Series, and Hirox Co. Ltd with its HRX Series.
• Phaos Technology differentiates itself through integrated proprietary software, turn-key solutions, and reliable after-sales support, which are critical in a market with complex, high-value equipment.
• The company's gross margin of 41.8% for the six months ended October 31, 2025, is a significant improvement from 12.7% in the prior year, suggesting better cost management or product mix compared to its earlier performance, but specific industry benchmarks for these competitors are not provided for direct comparison.
• The company's reliance on a few major customers (top 5 accounted for 85% of revenue) and geographic concentration (83.3% from Singapore) is higher than typical diversified industry leaders, indicating a higher risk profile compared to global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Not a party to any significant legal proceedings in Singapore as of the date of the prospectus.
• Not aware of any legal proceedings outside of Singapore.

Related Party Transactions

• Received interest-free, unsecured, and due-on-demand loans from major shareholder Tonghuai SG Enterprise Pte. Ltd. totaling S$3,755,423 (US$2,886,043) as of October 31, 2025.
• The interest-free nature of these loans represents a benefit to the Company not available in arms-length transactions.
• No other related party transactions occurred during the six months ended October 31, 2024 and 2025, or the years ended April 30, 2024 and 2025, other than the loan from the major shareholder.

Stakeholder Impact

• **Shareholders:** Face significant risk of investment loss due to recurring operating losses and substantial doubt about the company's ability to continue as a going concern. Dilution is expected for new investors. The dual-class share structure limits the influence of Class A shareholders. The IPO provides liquidity but long-term profitability is uncertain.
• **Employees:** Workforce reduction from 25 to 10 full-time employees as of October 31, 2025, indicates restructuring and potential job insecurity, though it aims to reduce cash burn. The company plans to hire additional personnel for growth.
• **Customers:** Benefit from advanced microscopy solutions, integrated software, turn-key solutions, and reliable after-sales support. However, high customer concentration means a loss of a major customer could impact product availability or service quality.
• **Suppliers:** Strong and stable relationships are emphasized, but supply chain interruptions and fluctuations in material prices could affect the company's ability to procure components, potentially impacting suppliers' business.
• **Creditors:** Exposed to risk due to the company's going concern doubts and reliance on related-party loans. The outstanding bank loan is secured by personal guarantees from management.

Next Steps

• Expand business and operations through joint ventures and/or strategic alliances in Southeast Asia (Indonesia, Thailand, Philippines, Vietnam).
• Strengthen global presence via marketing, shifting to digital marketing in Asia and targeting the Middle East, US, and Europe through exhibitions.
• Continue to expand the distribution network to increase market penetration in existing and new markets.
• Widen product range through continuous improvements, new product series development (e.g., for digital pathology), and building new technologies (IoT, cloud computing, Optical Coherence Tomography) into existing products.
• Provide calibration and certification services to existing and new customers by Q2 2025 to generate recurring income.
• Hire more qualified accounting personnel with U.S. GAAP and SEC reporting experience to strengthen financial reporting.
• Implement regular and continuous U.S. GAAP accounting and financial reporting training programs for accounting and financial reporting personnel.
• Engage an external consulting firm to assist with Sarbanes-Oxley compliance and internal control improvement.
• Maintain listing of Class A Ordinary Shares on Nasdaq Stock Market, NYSE, or NYSE American for at least three years after the Closing Date.
• PT Neura Integrasi Solusi is pursuing ISO 13485 certification to qualify for selling medical equipment to hospitals and biomedical institutions.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by recurring losses, a significant accumulated deficit, and negative operating cash flow. While a recent IPO provided some capital, the underlying business performance shows a drastic revenue decline in the last fiscal year and high customer/geographic concentration. The identified material weaknesses in internal controls further compound the risk. Despite innovative technology, the severe financial distress and operational challenges make the stock a high-risk investment with a strong likelihood of further price depreciation.

Keywords

Microscopy, Super-resolution imaging, AI software, Optical technology, Precision measurement, Nanometer observation, Biomedical scanning, Digital pathology, SEC filing, F-1, IPO, Cayman Islands, Singapore, Vietnam, Financial reporting, Corporate governance, Risk management, Share offering, Warrants